Publicaciones en las que colabora con Pablo Miguel Barreiro García (7)

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

2010

  1. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2007

  1. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444

  2. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391

  3. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476

  4. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982

2005

  1. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662